You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
Among older adults, APOE4‐related associations with neuroimaging outcomes are more pronounced in women than men. At midlife, a critical period for prevention and treatment of risk factors for cognitive decline, the influence of APOE4 genotype on women's cognitive and brain health is subtle. Therefore, there is a need for early biomarkers of brain vulnerabilities in female APOE4 carriers. Here, we examined APOE4‐related differences in patterns of activation and hippocampal functional connectivity during word encoding in cognitively normal midlife women and the associations of these patterns with verbal memory performance and plasma Alzheimer's disease (AD) biomarkers.
Method
Women participating in MsBrain, a cohort study of brain health in midlife women, completed functional magnetic resonance imaging assessments during verbal encoding and recognition tasks. We measured both activation patterns and hippocampal functional connectivity, the latter using generalized psychophysiological interaction analyses (SPM12, Conn) with AlphaSim (AFNI) to correct for multiple comparisons. APOE4 group differences (carriers [E3E4 and E4E4] vs. non‐carriers [E3E3]) were tested using linear regression. Associations of neuroimaging indices with verbal memory (California Verbal Learning Test measures [CVLT learning, semantic clustering]) and plasma AD biomarkers (Aβ42/40, p‐tau 181, p‐tau 231) were tested via linear regression. All analyses adjusted for age, race, and education.
Result
In 145 women (mean age=59.1 years, 86.2% white, 24.1% APOE4+), APOE4 carriers and non‐carriers did not significantly differ on in‐scanner verbal recognition performance, CVLT measures, or plasma AD biomarkers. During verbal encoding, APOE4 non‐carriers had significantly greater activation and hippocampal functional connectivity in several regions compared to APOE4 carriers (Figure 1). Of the regions showing greater activation among non‐carriers, left inferior frontal gyrus activation was positively associated with CVLT measures, and greater connectivity from the left hippocampus to the left declive/fusiform was associated with lower p‐tau 181 levels (Figure 2).
Conclusion
Female midlife APOE4 carriers have decreased activity and connectivity in key memory regions during word encoding compared to non‐carriers, despite showing similar cognitive performance and plasma amyloid and tau levels. Associations of certain connectivity outcomes with AD biomarkers suggest relevance to AD pathogenesis. These functional brain patterns may emerge earlier than the adverse effects of APOE4 genotype on cognition and brain.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Psychology, University of Illinois Chicago, Chicago, IL, USA,
2 Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA,
3 University of Pittsburgh Alzheimer's Disease Research Center, Pittsburgh, PA, USA,, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA,
4 Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA,, University of Pittsburgh Alzheimer's Disease Research Center, Pittsburgh, PA, USA,
5 Department of Neurology, and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA,
6 Departments of Psychiatry, Psychology, and Obstetrics & Gynecology, University of Illinois Chicago, Chicago, IL, USA,





